CP 2090

Drug Profile

CP 2090

Alternative Names: CP-2090

Latest Information Update: 03 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ube Industries
  • Class Anti-inflammatories; Antifibrotics; Hepatoprotectants; Small molecules
  • Mechanism of Action Lysophosphatidic acid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis

Most Recent Events

  • 29 Mar 2018 Curadim Pharma acquires rights from Ube Industries to develop, manufacture and market CP 2090 formulations worldwide
  • 28 Mar 2018 Early research in Idiopathic pulmonary fibrosis in Japan (unspecified route)
  • 28 Mar 2018 Early research in Non-alcoholic steatohepatitis in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top